SS Innovations International, Inc., a developer of surgical robotic technologies, has completed a private placement of its common stock that generated approximately $18.6 million in gross proceeds. The financing, which closed on March 6, 2026, involved the sale of 5,774,839 shares of common stock and saw substantial participation from the company's own directors and executive officers. This capital infusion represents a critical step in the company's strategic growth plan, particularly as it prepares to enter highly regulated markets in the United States and Europe.
The private placement consisted of two components. An aggregate of 1,300,006 shares were sold at an average price of $4.00 per share to Chairman and CEO Dr. Sudhir Srivastava, Vice-Chairman Dr. Frederic H. Moll, and director Tim Adams, totaling approximately $5.2 million. Additionally, 4,474,833 shares were sold at $3.00 per share to existing and new investors, led by existing shareholder Manipal Global Health Services, generating approximately $13.4 million. The significant insider investment demonstrates leadership confidence in the company's trajectory and commitment to making robotic surgery more accessible globally.
According to the company, the net proceeds will be used for working capital and general corporate purposes, including advancing global expansion efforts. Dr. Srivastava stated that the financing will support growth initiatives in India and other existing markets while preparing for entry into the United States and European Union markets. The company anticipates that the U.S. Food and Drug Administration will complete its review of the 510(k) premarket notification for the SSi Mantra surgical robotic system by mid-2026 and believes it can obtain European Union CE marking certification in the same year. These regulatory milestones are essential for market access in regions that represent the largest opportunities for surgical robotics adoption.
The company's SSi Mantra surgical robotic system is a modular, multi-arm system with advanced technology features that has been clinically validated in India in more than 100 different types of surgical procedures. More information about the company is available at https://ssinnovations.com. In connection with a $2.5 million investment by one non-affiliate investor, SS Innovations will pay a FINRA member firm a cash commission of $175,000 and issue five-year warrants to purchase 41,667 shares at an exercise price of $3.45 per share. The securities sold in the private placement have not been registered under the Securities Act of 1933 and may not be offered or sold in the United States absent registration or an applicable exemption.
This financing round is important because it provides the capital necessary to navigate complex regulatory pathways in key markets while supporting continued innovation and commercialization efforts. The surgical robotics market is highly competitive and capital-intensive, requiring significant resources for clinical trials, regulatory submissions, and market development. The insider participation, particularly from experienced medical technology leaders like Dr. Moll who previously founded Intuitive Surgical, signals strong belief in the technology's potential to disrupt the global surgical robotics landscape dominated by a few major players.
